BR112022022427A2 - Tratamento de infecção, doença ou distúrbio viral com o uso de um agonista de s1r seletivo - Google Patents

Tratamento de infecção, doença ou distúrbio viral com o uso de um agonista de s1r seletivo

Info

Publication number
BR112022022427A2
BR112022022427A2 BR112022022427A BR112022022427A BR112022022427A2 BR 112022022427 A2 BR112022022427 A2 BR 112022022427A2 BR 112022022427 A BR112022022427 A BR 112022022427A BR 112022022427 A BR112022022427 A BR 112022022427A BR 112022022427 A2 BR112022022427 A2 BR 112022022427A2
Authority
BR
Brazil
Prior art keywords
agonist
selective
disease
disorders
treatment
Prior art date
Application number
BR112022022427A
Other languages
English (en)
Portuguese (pt)
Inventor
Hayden Michael
Geva Michal
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of BR112022022427A2 publication Critical patent/BR112022022427A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022022427A 2020-05-04 2021-05-04 Tratamento de infecção, doença ou distúrbio viral com o uso de um agonista de s1r seletivo BR112022022427A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019465P 2020-05-04 2020-05-04
PCT/IL2021/050507 WO2021224914A1 (en) 2020-05-04 2021-05-04 Treatment of viral infection, disease or disorder using a selective s1r agonist

Publications (1)

Publication Number Publication Date
BR112022022427A2 true BR112022022427A2 (pt) 2022-12-13

Family

ID=78467884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022427A BR112022022427A2 (pt) 2020-05-04 2021-05-04 Tratamento de infecção, doença ou distúrbio viral com o uso de um agonista de s1r seletivo

Country Status (9)

Country Link
US (1) US20230100072A1 (zh)
EP (1) EP4146208A4 (zh)
JP (1) JP2023534095A (zh)
CN (1) CN115551505A (zh)
AU (1) AU2021266476A1 (zh)
BR (1) BR112022022427A2 (zh)
CA (1) CA3176917A1 (zh)
IL (1) IL297932A (zh)
WO (1) WO2021224914A1 (zh)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064654A1 (en) * 2010-11-08 2012-05-18 Inhibikase Therapeutics, Inc. Methods for prevention and treatment of influenza
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
MX2019002265A (es) * 2016-08-24 2019-10-30 Prilenia Therapeutics Dev Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
FR3057773B1 (fr) * 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
WO2021195470A2 (en) * 2020-03-27 2021-09-30 Vanda Pharmaceuticals Inc. Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2
EP4110314B1 (en) * 2020-04-07 2024-06-05 Hista RX LLC Methods and pharmaceutical compositions for treating and preventing acute respiratory distress syndrome associated with viral infections

Also Published As

Publication number Publication date
JP2023534095A (ja) 2023-08-08
WO2021224914A1 (en) 2021-11-11
EP4146208A1 (en) 2023-03-15
IL297932A (en) 2023-01-01
CA3176917A1 (en) 2021-11-11
CN115551505A (zh) 2022-12-30
EP4146208A4 (en) 2024-05-22
AU2021266476A1 (en) 2022-11-24
US20230100072A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
BR112022016413A2 (pt) Método para o tratamento ou prevenção do coronavírus causado pelo vírus coronavírus da síndrome respiratória aguda grave 2, composto, e, uso de um composto
MX2021014742A (es) Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
BR112019010646A2 (pt) métodos de tratamento de condições inflamatórias
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
BRPI0514043A (pt) medicamentos para tratar doença respiratória crÈnica
BR112022016360A2 (pt) Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
BR112022023048A2 (pt) Tratamento de combinação de distúrbios hepáticos
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
BR112021018262A2 (pt) Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina
ECSP22077573A (es) Método para el tratamiento de afecciones asociadas a covid-19
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
BR112021022602A2 (pt) Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BR112022022427A2 (pt) Tratamento de infecção, doença ou distúrbio viral com o uso de um agonista de s1r seletivo
BR112022018235A2 (pt) Método de tratamento, método para tratar síndrome do desconforto respiratório agudo, método para inibir uma resposta de citocina em um paciente, método para tratar lesão renal aguda e método para tratar trombose
BR112023000308A2 (pt) Uso de taurolidina contra vírus
BR112022008580A2 (pt) Métodos para tratar transtornos depressivos
BR112021020893A2 (pt) Uso de cocristais de tramadol e celecoxib para o tratamento de dor, ao mesmo tempo que reduzindo a suscetibilidade a abuso do tramadol
BR112022010733A2 (pt) Métodos para tratar dor